Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00513240 · ClinicalTrials.gov registry record · Phase 1

Erythropoetin Neuroprotection for Neonatal Cardiac Surgery

A Phase 1 study, sponsored by Baylor College of Medicine.

Completed
Registry status
Phase 1
Development phase
62
Enrollment target

NCT00513240: Completed Phase 1 study, sponsored by Baylor College of Medicine.

NCT00513240 is a Phase 1 study that has completed, run by Baylor College of Medicine. The registered enrollment target is 62 participants, roughly in line with the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00513240, a Phase 1 study, has completed, sponsored by Baylor College of Medicine.

COMPLETED
Registry status
Phase 1
Development phase
62 participants
Enrollment target

Study Summary

Brain problems occur in neonatal open heart surgery with a frequency of 20-70%, seen on neurological examination, brain imaging such as magnetic resonance imaging (MRI), or long term development problems such as learning disorders and hyperactivity syndromes. This study aims to determine if erythropoetin, a natural hormone made in the body, protects the brain from damage when given in high doses before and during neonatal open heart surgery. We will use brain MRI, brain wave tests (EEG), neurological examination, and long term developmental outcome testing to see if erythropoetin is better than salt water injection (placebo) in protecting the brain.

Primary Outcome

TMS is a measure of developmental maturity of the brain as assessed from T1 and T2-weighted images, grading myelination, cortical infolding, involution of the germinal matrix, and presence of bands of migrating glial cells. The brain MRIs were reviewed for infarction, hemorrhage, white matter injury (WMI), or dural sinovenous thrombosis (DVST). Injuries in each category are scored 0 for none, 1 for mild, 2 for moderate, 3 for severe. The score in each category is then multiplied by a proposed ou

Interventions

  • DRUG Normal saline
  • DRUG Erythropoetin

Trial Details

FieldValue
Enrollment Target 62 participants
Start Date 2006-09
Est. Completion 2015-09
Phase Phase 1
Baylor College of Medicine

616 total trials

What the finished NCT00513240 record still lists

NCT00513240 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 62 participants, a relatively small participant target, roughly in line with the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target.

The record links to 0 conditions, and to 2 interventions - of which Normal saline is the first listed.

NCT00513240 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00513240 about?

NCT00513240 is a clinical study titled "Erythropoetin Neuroprotection for Neonatal Cardiac Surgery". Brain problems occur in neonatal open heart surgery with a frequency of 20-70%, seen on neurological examination, brain imaging such as magnetic resonance imaging (MRI), or long term development problems such as learning disorders and hyperactivity syndromes. This study aims to determine if erythrop...

What is the current status of trial NCT00513240?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 62 participants. The study started on 2006-09. Estimated completion is 2015-09.

What interventions are being tested in trial NCT00513240?

The interventions under investigation include: Normal saline (DRUG), Erythropoetin (DRUG).

Who is sponsoring clinical trial NCT00513240?

This trial is sponsored by Baylor College of Medicine, which has 616 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT00513240's enrollment target sits among peer trials

62 824th of 2000 higher than 1,173 of 2,000 other Phase 1 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03231150 · 62 participants · NA

    Plantar Fasciitis Randomized Clinical Control Trial

  • NCT03458676 · 62 participants · NA

    Radiologic Pathologic Correlation of Advanced MR Imaging to Guide the Biopsy of Cerebral Malignancies

  • NCT03596086 · 62 participants · Phase 1

    HSV-tk + Valacyclovir + SBRT + Chemotherapy for Recurrent GBM

  • NCT03603405 · 62 participants · Phase 1

    HSV-tk and XRT and Chemotherapy for Newly Diagnosed GBM

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00513240, the US trial registry maintained by the National Library of Medicine. NCT00513240 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.